Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.170
+0.100 (9.35%)
At close: Sep 2, 2026, 4:00 PM EDT
1.170
0.00 (0.00%)
After-hours: Sep 2, 2026, 4:04 PM EDT
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$762,327
Profits / Employee
-$379,374
Market Cap
8.55M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| Soligenix | 14 |
| Ensysce Biosciences | 10 |
| CNS Pharmaceuticals | 8 |
| Traws Pharma | 7 |
| Alzamend Neuro | 6 |
| Acurx Pharmaceuticals | 4 |
IMRN News
- 6 weeks ago - Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year - GlobeNewsWire
- 1 month ago - Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy - GlobeNewsWire
- 4 months ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 4 months ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 6 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 6 months ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 7 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 7 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire